A Randomized Phase 3 Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine With Lomustine Compared to Lomustine Alone in Patients With AA That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 27 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Eflornithine (Primary) ; Lomustine
Indications Anaplastic astrocytoma
Focus Registrational; Therapeutic Use
Acronyms STELLAR; STELLAR
Sponsors Orbus Therapeutics

Most Recent Events

22 Nov 2024 According to an Orbus Therapeutics media release,results from the Phase 3 STELLAR study will be presented at an upcoming medical conference.
22 Nov 2024 According to an Orbus Therapeutics media release, results of this study were presented at the Society for Neuro-Oncology Annual Meeting held in Houston, Texas.
22 Nov 2024 Results presented in the Orbus Therapeutics Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight